Abstract:
Objective:To explore the clinical efficacy of three dimensional (3D) laparoscopic sleeve gastrectomy (LSG) in the treatment of obesity combined with type 2 diabetes mellitus.
Methods:The retrospective crosssectional study was conducted. The clinical data of 28 patients with obesity combined with type 2 diabetes mellitus who were admitted to the Qinghai Red Cross Hospital between January 2013 and April 2016 were collected. All the patients underwent 3D LSG. Observation indicators: (1) surgical and postoperative recovery situations; (2) followup and metabolic indexes changes. Followup using outpatient examination and telephone interview was performed to detect complications of patients after discharge and usages of antidiabetic drugs or insulin up to February 2017. Body mass, body mass index (BMI), hemoglobin (Hb), albumin (Alb), fasting serum Cpeptide, fasting blood sugar, 2hours postprandial blood glucose (2HPBG) and glycosylated hemoglobin (GHb) were detected at month 1, 3, 6 and 12 postoperatively. Measurement data with normal distribution were represented as

±s. Repeated measurement data were analyzed by the repeated measures ANOVA. Count data were evaluated by the proportion.
Results:(1) Surgical and postoperative recovery situations: 28 patients underwent successful 3D LSG, without conversion to open surgery. Operation time, volume of intraoperative blood loss, time of postoperative gastrointestinal function recovery and time of postoperative drainage tube removal were (133±20)minutes, (45±22)mL, (2.5±1.2)days and (3.4±0.9)days, respectively. There were no postoperative complications and perioperative death. Duration of hospital stay was (7.1±1.5)days. (2) Followup and metabolic indexes changes: 28 patients were followed up for 6-12 months, with a median time of 8 months. During the followup, there was no death or severe complications. Body mass, BMI, Hb, Alb, fasting serum Cpeptide, fasting blood sugar, 2HPBG and GHb from preoperation to month 1, 3, 6 and 12 postoperatively were decreased from (113±26)kg to (78±14)kg, from (44±6)kg/m
2 to (35±5)kg/m
2, from (157±19)g/L to (140±13)g/L, from (43±5)g/L to (40±4)g/L, from (2.50±0.37)μg/L to (1.20±0.33)μg/L, from (10.5±2.0)mmol/L to (5.6±0.5)mmol/L, from (16.3±3.1)mmol/L to (7.9±0.9)mmol/L, from 9.2%±0.9% to 6.8%±0.6% with statistically significant differences between preoperative and postoperative indicators (F=396.47, 328.20, 111.10, 21.28, 161.06, 127.80, 243.40, 234.64, P<0.05), and showing a downward trend. Of 28 patients, 25 had complete remission of type 2 diabetes mellitus at 12 months postoperatively and 3 had partial remission, with an effective rate of 100.0%(28/28). The excess weight loss was 63%±16%.
Conclusion: 3D LSG is safe and effective in the treatment of obesity combined with type 2 diabetes mellitus, with a good shortterm outcome.